Basilea Pharmaceutica AG took a heavy pounding on the Swiss Stock Exchange in Zurich Tuesday, on news that the company had received an approvable letter from the FDA in response to its new drug application filing for the cephalosporin antibiotic ceftobiprole. (BioWorld International) Read More
